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unlikely. Some bias due to above average socio-economic status
of the insured population cannot be excluded.
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FACTORS INFLUENCING ZIPRASIDONE PRESCRIBED DOSES
AMONG MEDICAID PATIENTS WITH SCHIZOPHRENIA
Mullins CD, Kuznik A
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OBJECTIVE: To describe factors which are associated with vari-
ations in the prescribed average daily dose of ziprasidone for the
treatment of schizophrenia. METHODS: We identiﬁed continu-
ously enrolled patients with a diagnosis of schizophrenia (ICD-
9 code 295.xx) between January 2001 and June 2003 from
Maryland Medicaid. The average daily dose prescribed was
deﬁned as the total amount dispensed divided by the days of
therapy. The effect of socio-demographic factors, recent hospi-
talization, psychiatric co-morbidities, and concurrent psychiatric
medication on the average daily dose prescribed was estimated
using ordinary least squares (OLS) regression. RESULTS: In the
sample of 1197 patients who met the inclusion criteria, the mean
average dose prescribed was 92mg per day (S.D.: 50mg). Males
were prescribed an 8mg higher average daily dose as compared
to females (p = 0.007). African Americans were prescribed 9mg
less as compared to Caucasians (p = 0.005). The average daily
dose prescribed increased if the patient was concurrently treated
with antidepressants by 8mg (p = 0.018), with antipsychotics by
16mg (p < 0.001), and with anticonvulsants by 12mg (p =
0.001). Patients who had a psychiatric hospitalization during the
30 days prior to initiation of therapy were prescribed average
daily doses that were 8mg higher, but this increase was not sta-
tistically signiﬁcant (p = 0.055). Patient age, the number of psy-
chiatric co-morbidities, and concurrent treatment with antimanic
and antianxiety medication were not found to statistically affect
prescribing patterns. CONCLUSION: Schizophrenia patients’
gender, race, and concurrent treatment medication signiﬁcantly
affect the decision makers prescribing patterns of ziprasidone in
terms of the average daily dose.
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OBJECTIVES: To evaluate 6-month clinical and economic out-
comes following initiation of long-acting injectable risperidone
(LAIR) in patients with schizophrenia/schizoaffective disorder.
METHODS: Data are collected via a secured web-based system,
retrospectively for 12-months and prospectively for 2-years.
Patient demographics, treatment and hospitalisation history,
reason for initiating new treatment, Clinical Global Impres-
sion—Severity (CGI-S), Global Assessment of Functioning (GAF)
and adverse event data are collected. This interim analysis
includes the ﬁrst 991 patients in Germany with at least 6 months
follow-up or who discontinued treatment during this 6 month
period. RESULTS: Of the 991 patients, 56% were male. Mean
age was 43 (±14) years, mean duration of illness at initiation of
LAIR was 10 (±10) years. A total of 79% were diagnosed with
schizophrenia whilst 17% had schizoaffective disorder. After 6-
months, 75% of patients still received their original starting
dose. Compared with the preceding 6-month period, fewer
patients required full hospitalisations (34% vs. 20%; p < 0.001).
Decreases from baseline were seen in the concomitant use of anti-
cholinergics (13.3% to 6.1%), antidepressants (18.1% to
11.8%), mood stabilisers (9.8% to 7.1%), benzodiazepines
(17.3% to 8.4%), and somatic medication (14.7% to 8.5%; all
comparisons p < 0.001). Compared to baseline, CGI-S ratings
improved from 4.7 to 3.8, and patient functioning (GAF)
increased from 46.7 to 58.0 at 6-months (both p < 0.001); 13%
of patients discontinued treatment with LAIR. Most frequent
reason (3.5%) was patient/family choice; 1.2% discontinued due
to adverse event. CONCLUSIONS: The 6-month interim data
show that the majority of patients initiated on LAIR remained
on stable doses. Discontinuation rates were low. Need for inpa-
tient care was reduced, as was use of psychotropic and somatic
concomitant medication. There was signiﬁcant and clinically rel-
evant improvement in illness and functioning. Longer term data
with larger sample size are being accrued to further explore these
outcomes over time.
PMH35
ARE INDIRECT COSTS MEASUREMENTS RELEVANT IN A
SCHIZOPHRENIC PATIENTS POPULATION? AN OVERVIEW OF
A LONGITUDINAL STUDY IN FRANCE
Primus C1, Dinet J1, Martin P2, Gury C1
1sanoﬁ-aventis France, Paris, France; 2CREST, Paris, France
OBJECTIVES: From a longitudinal study, we observed the socio-
economic proﬁle and the occupational situation of a cohort of
schizophrenic patients over 1 year and we made an estimate of
the indirect costs in this population. METHODS: Occupations,
sources of income, health care and social situation were reported
regularly over a 1-year period by a group of 538 schizophrenic
outpatients. We speciﬁcally studied the population already inte-
grated into the workplace. Number and duration of work
absences were basic data for the calculation of indirect costs. In
this subgroup, we adopted the perspective of the Sickness Fund
(SF). The costing was performed by combining number and
duration of work absences, patient income levels in 2002, annual
number of workdays, SF rules for the coverage of workdays lost.
RESULTS: In our sample of 538 schizophrenic patients, 2% were
managers, 15% were white-collars, 5% were blue-collars, 8%
were unemployed and the rest of the population (70%) lived
without occupations or in occupation-aided structure. Work
absences occurred in 54% of managers with a median duration
of 184 days; this rate is at 36% for white-collars with a median
duration of 83 days; this rate is at 19% for blue-collars with a
median duration of 30 days. The median costs over 1-year due
to absenteeism at work were €7419, €3071, and €1100 for man-
agers, white-collars and blue-collars respectively. CONCLU-
SIONS: More than a quarter of our sample was employed and
integrated into society. We found that managers seemed to gen-
erate highest work absences in terms of number, duration and
costs; the position of managers and the level of related-stress
might have an impact on the natural course of the disease.
According to our ﬁndings, it is reasonable to estimate the indi-
rect costs of schizophrenia more accurately in the future.
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